XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
(NASDAQ: XBIT) Delayed: 2.31 --0 (-0%)
Previous Close $2.31    52 Week High $25.00 
Open $2.34    52 Week Low $6.36 
Day High $2.35    P/E N/A 
Day Low $2.30    EPS $0.00 
Volume 43,575